NCT03907852 - Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

November 19, 2024

Study Completion Date

November 2, 2028

Conditions

MesotheliomaMesothelioma, MalignantMesothelioma; PleuraMesotheliomas PleuralMesothelioma PeritoneumCholangiocarcinomaCholangiocarcinoma RecurrentOvarian CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticHigh Grade Ovarian Serous Adenocarcinoma

Interventions

BIOLOGICAL

gavo-cel

DRUG

fludarabine

lymphodepletion chemotherapy

DRUG

cyclophosphamide

lymphodepletion chemotherapy

DRUG

Nivolumab

immuno-oncology agent

DRUG

Ipilimumab

immuno-oncology agent

Trial Locations (11)

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Philadelphia

20814

National Cancer Institute, Bethesda

27705

Duke University, Durham

33136

University of Miami Sylvester Cancer Center, Miami

37203

SCRI Oncology Partners, Nashville

60637

University of Chicago Medical Center, Chicago

77030

University of Texas MD Anderson Cancer Center, Houston

94143

University of California, San Francisco, San Francisco

M5G 2C1

Princess Margaret Cancer Centre, Toronto